Non-coding RNAs represent a majority of the human transcriptome. However, less is known
about the functions and regulatory mechanisms of most non-coding species. Moreover, little …

Background Combined therapy with dabrafenib plus trametinib was approved in several
countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an …

The BRAF gene is commonly involved in normal processes of cell growth and differentiation.
The BRAF (V600E) mutation is found in several human cancer, causing an increase of cell …

Background: Mutations of v-raf murine sarcoma viral oncogene homolog B (BRAF) are
commonly identified in papillary and anaplastic thyroid carcinoma and are associated with …

Background: Molecular testing for oncogenic gene mutations and chromosomal
rearrangements plays a growing role in the optimal management of thyroid nodules, yet …

Being located in a gene desert region on 9q21. 11-q21. 12, BRAF-activated non-protein
coding RNA (BANCR) is an lncRNA with 693 bp length. It has been discovered in 2012 in a …

Papillary thyroid carcinoma (PTC) is heterogeneous and its molecular characteristics remain
elusive. We integrated transcriptomic sequencing, genomic analysis and clinicopathologic …

Background: The BRAF mutation has been shown to be associated with aggressive
clinicopathologic characteristics of papillary thyroid cancer (PTC). However, several studies …

Background Papillary thyroid carcinoma (PTC) is a common endocrine neoplasm with a
recent increase in incidence in many countries. Although PTC has been explored by gene …

The B-Raf protein is a key signaling molecule in the mitogen activated protein kinase
(MAPK) signaling pathway and has been implicated in the pathogenesis of a variety of …